Loading company
In8bio, Inc.
INAB · Nasdaq · ·
Next earnings: November 5, 2026
$1.30+1.2%Sep 29 close
- 1M
- +25.6%
- 6M
- -5.1%
- 1Y
- -40.1%
- 5Y
- -99.4%
INAB · Nasdaq · ·
Next earnings: November 5, 2026
$1.30+1.2%Sep 29 close
In8bio, Inc. is scheduled to report next on November 5, 2026. The date comes from Nasdaq’s earnings calendar, and companies sometimes move it.
The quarter ending June 30, 2026, against the same quarter a year earlier.
| Measure | 3 months toJun 30, 2026 | 3 months toJun 30, 2025 | Change |
|---|---|---|---|
| Profit | -$4.8M | -$5.1M | +6.14% |
| Profit per share | -$0.25 | -$1.24 | +79.84% |
| Free Cash Flow | -$4M | -$3.1M | -27.42% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
In8bio, Inc. has no earnings call transcript available.
“The second quarter marked an important period of scientific and clinical validation for γδ T cell therapeutics and IN8bio. Our γδ TCE platform is progressing, with INB-619 advancing into initial animal models. We are pleased to remain on track for reporting initial in vivo data this year,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
Releases land after the close or before the open, so the move is the session that follows.
IN8bio is a clinical-stage biopharmaceutical company developing γδ T cell and γδ T cell engager (TCE) product candidates to address unmet medical needs. γδ T cells are a specialized population of T cells that possess unique properties, including the ability to differentiate between healthy and diseased tissue. The Company’s pipeline is anchored by INB-600, a novel γδ T cell engager platform with potential applications across oncology and autoimmune indications. IN8bio is also advancing INB-100, an allogeneic γδ T cell candidate for adult patients with high-risk leukemias undergoing haploidentical stem cell transplantation, and INB-200/400, an autologous genetically modified γδ T cell candidate for newly diagnosed glioblastoma (GBM).
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from In8bio, Inc.’s Item 2.02 8-K filed August 6, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.